Literature DB >> 28521418

Overexpression of E3 ubiquitin ligase tripartite motif 32 correlates with a poor prognosis in patients with gastric cancer.

Masahiro Ito1, Kazuhiro Migita1, Sohei Matsumoto1, Kohei Wakatsuki1, Tetsuya Tanaka1, Tomohiro Kunishige1, Hiroshi Nakade1, Mitsuhiro Nakatani1, Yoshiyuki Nakajima1.   

Abstract

Tripartite motif protein (TRIM) 32 belongs to the TRIM family, which is composed of RING finger, B-box and coiled-coil domains. TRIM32 has been reported to function as an enzyme 3 ubiquitin ligase and is overexpressed in numerous types of cancer. The present study evaluated the clinical significance of TRIM32 expression levels in gastric cancer. The current study also investigated the TRIM32 expression levels in 142 patients with gastric cancer using immunohistochemistry and examined its clinical importance and potential as a prognostic marker. Furthermore, the function of TRIM32 was examined in vitro. High TRIM32 expression levels were detected in gastric cancer tissues. The postoperative overall and relapse-free survival rates were significantly reduced in patients with tumors with high levels of TRIM32 expression compared with those with tumors expressing low levels of TRIM32. Tumors expressing high levels of TRIM32 were associated with an increased risk of postoperative recurrence, particularly hematogenous recurrence. Multivariate analysis identified TRIM32 status as an independent prognostic factor. Furthermore, TRIM32 gene silencing induced apoptosis and inhibited the proliferation of gastric cancer cells in vitro. Therefore, TRIM32 expression levels may be of potential prognostic value in gastric cancer.

Entities:  

Keywords:  enzyme 3 ubiquitin ligase; gastric cancer; hematogenous recurrence; prognostic factor; tripartite motif 32

Year:  2017        PMID: 28521418      PMCID: PMC5431222          DOI: 10.3892/ol.2017.5806

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

1.  Loss of COP1 expression determines poor prognosisin patients with gastric cancer.

Authors:  Genta Sawada; Hiroki Ueo; Tae Matsumura; Ryutaro Uchi; Masahisa Ishibashi; Kosuke Mima; Junji Kurashige; Yusuke Takahashi; Sayuri Akiyoshi; Tomoya Sudo; Keishi Sugimachi; Yuichiro Doki; Masaki Mori; Koshi Mimori
Journal:  Oncol Rep       Date:  2013-08-08       Impact factor: 3.906

Review 2.  Therapeutic strategies within the ubiquitin proteasome system.

Authors:  A G Eldridge; T O'Brien
Journal:  Cell Death Differ       Date:  2010-01       Impact factor: 15.828

3.  The interaction of Piasy with Trim32, an E3-ubiquitin ligase mutated in limb-girdle muscular dystrophy type 2H, promotes Piasy degradation and regulates UVB-induced keratinocyte apoptosis through NFkappaB.

Authors:  Amador Albor; Sally El-Hizawi; Elizabeth J Horn; Melanie Laederich; Patrick Frosk; Klaus Wrogemann; Molly Kulesz-Martin
Journal:  J Biol Chem       Date:  2006-06-30       Impact factor: 5.157

Review 4.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

5.  Aberrant expression of the autocrine motility factor receptor correlates with poor prognosis and promotes metastasis in gastric carcinoma.

Authors:  Zhen Huang; Neng Zhang; Lang Zha; Hong-Chao Mao; Xuan Chen; Ji-Feng Xiang; Hua Zhang; Zi-Wei Wang
Journal:  Asian Pac J Cancer Prev       Date:  2014

6.  Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.

Authors:  J F Robertson; R I Nicholson; N J Bundred; E Anderson; Z Rayter; M Dowsett; J N Fox; J M Gee; A Webster; A E Wakeling; C Morris; M Dixon
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

7.  Prognostic impact of RING box protein-1 (RBX1) expression in gastric cancer.

Authors:  Kazuhiro Migita; Tomoyoshi Takayama; Sohei Matsumoto; Kohei Wakatsuki; Tetsuya Tanaka; Masahiro Ito; Satoshi Nishiwada; Yoshiyuki Nakajima
Journal:  Gastric Cancer       Date:  2013-11-29       Impact factor: 7.370

8.  MDM2 is a useful prognostic biomarker for resectable gastric cancer.

Authors:  Yang Ye; Xuan Li; Jingjing Yang; Shuhan Miao; Shouyu Wang; Yansu Chen; Xiaowei Xia; Xuming Wu; Jianbing Zhang; Yan Zhou; Song He; Yongfei Tan; Fulin Qiang; Gang Li; Oluf Dimitri Røe; Jianwei Zhou
Journal:  Cancer Sci       Date:  2013-03-05       Impact factor: 6.716

9.  Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer.

Authors:  Yoshimasa Kosaka; Hiroshi Inoue; Takahiro Ohmachi; Takeshi Yokoe; Toshifumi Matsumoto; Koshi Mimori; Fumiaki Tanaka; Masahiko Watanabe; Masaki Mori
Journal:  Ann Surg Oncol       Date:  2007-06-28       Impact factor: 5.344

10.  Tripartite motif protein 32 facilitates cell growth and migration via degradation of Abl-interactor 2.

Authors:  Satoshi Kano; Naoto Miyajima; Satoshi Fukuda; Shigetsugu Hatakeyama
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

View more
  9 in total

1.  Drosophila TRIM32 cooperates with glycolytic enzymes to promote cell growth.

Authors:  Simranjot Bawa; David S Brooks; Kathryn E Neville; Marla Tipping; Md Abdul Sagar; Joseph A Kollhoff; Geetanjali Chawla; Brian V Geisbrecht; Jason M Tennessen; Kevin W Eliceiri; Erika R Geisbrecht
Journal:  Elife       Date:  2020-03-30       Impact factor: 8.140

2.  TRIM32 overexpression improves chemoresistance through regulation of mitochondrial function in non-small-cell lung cancers.

Authors:  Yaming Du; Wei Zhang; Binghui Du; Sheng Zang; Xinpeng Wang; Xin Mao; Zhansheng Hu
Journal:  Onco Targets Ther       Date:  2018-11-05       Impact factor: 4.147

Review 3.  The Tripartite Nexus: Autophagy, Cancer, and Tripartite Motif-Containing Protein Family Members.

Authors:  Michael A Mandell; Bhaskar Saha; Todd A Thompson
Journal:  Front Pharmacol       Date:  2020-03-11       Impact factor: 5.810

4.  TRIM32 Promotes the Growth of Gastric Cancer Cells through Enhancing AKT Activity and Glucose Transportation.

Authors:  Jianjun Wang; Yuejun Fang; Tao Liu
Journal:  Biomed Res Int       Date:  2020-01-21       Impact factor: 3.411

Review 5.  TRIM Proteins in Colorectal Cancer: TRIM8 as a Promising Therapeutic Target in Chemo Resistance.

Authors:  Flaviana Marzano; Mariano Francesco Caratozzolo; Graziano Pesole; Elisabetta Sbisà; Apollonia Tullo
Journal:  Biomedicines       Date:  2021-02-27

Review 6.  Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance.

Authors:  Huizhen Wang; Yida Lu; Mingliang Wang; Youliang Wu; Xiaodong Wang; Yongxiang Li
Journal:  J Mol Med (Berl)       Date:  2021-01-03       Impact factor: 4.599

Review 7.  Tumor suppressor p53 cross-talks with TRIM family proteins.

Authors:  Juan Liu; Cen Zhang; Xue Wang; Wenwei Hu; Zhaohui Feng
Journal:  Genes Dis       Date:  2020-07-16

8.  TRIM32 promotes cell proliferation and invasion by activating β-catenin signalling in gastric cancer.

Authors:  Changming Wang; Jiapeng Xu; Hongbing Fu; Yu Zhang; Xin Zhang; Dejun Yang; Zhenxin Zhu; Ziran Wei; Zunqi Hu; Ronglin Yan; Qingping Cai
Journal:  J Cell Mol Med       Date:  2018-08-05       Impact factor: 5.310

Review 9.  TRIM32: A Multifunctional Protein Involved in Muscle Homeostasis, Glucose Metabolism, and Tumorigenesis.

Authors:  Simranjot Bawa; Rosanna Piccirillo; Erika R Geisbrecht
Journal:  Biomolecules       Date:  2021-03-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.